SK-216

Cat. No.:	HY-122714
CAS No.:	654080-03-2
Molecular Formula:	$C_{29}H_{29}NNa_2O_6$
Molecular Weight:	533.52
Target:	PAI-1
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

SK-216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor that acts as an anti-metastatic agent for human osteosarcoma and inhibits lung metastasis of human osteosarcoma[1].

In Vitro

SK-216 (0-50 μM, 48 h) can inhibit the invasion of 143B cells in a dose-dependent manner, but does not affect cell proliferation and migration[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis [1]

Cell Line:	human osteosarcoma cell line 143B
Concentration:	0, 25, 50 μM
Incubation Time:	48 h
Result:	Inhibited PAI-1 expression by 40% at concentrations of 25 and 50 μM and lead to a significantly lower ratio of cell-invaded wells/total wells. Inhibited MMP-13 secretion in 143B cells.

In Vivo

SK-216 (i.p., 6.6 μg/200 μL in PBS, once every 3 days) inhibits lung metastasis of human osteosarcoma cells, but not tumor growth in primary tumors in male athymic nude mice with 143B-Luc cell model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-6-week-old male athymic nude mice with 143B-Luc cell[1]
Dosage:	6.6 μg/200 μL in PBS
Administration:	i.p., once every 3 days
Result:	Resulted in a significant reduction in PAI-1 expression levels in primary lesions in mice.

REFERENCES

[1]. Minori Tsuge, et al. SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma. Int J Mol Sci. 2018 Mar 5;19(3):736.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA